PARP and PARG inhibitors-new therapeutic targets in cancer treatment

Pathology and Oncology Research

Volumn 16, Issue 4, 2010, Pages 469-478

  Fauzee, Nilufer Jasmine Selimah ^a   Pan, Juan ^a   Wang, Ya Lan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

PARG; PARG inhibitors; PARP; PARP inhibitors

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 AMINOBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ANTINEOPLASTIC AGENT; BENZAMIDE; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GEMCITABINE; GLYCOSIDASE; INO 1001; MK 4827; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLATINUM COMPLEX; POLY ADP RIBOSE GLYCOHYDROLASE; POLY ADP RIBOSE GLYCOHYDROLASE INHIBITOR; TANNIN; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADVANCED CANCER; APOPTOSIS; BRAIN TUMOR; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE ACTIVITY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS TUMOR; PROSTATE CANCER; RADIOSENSITIZATION; REVIEW; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GLYCOSIDE HYDROLASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 78149393537     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-010-9266-6     Document Type: Review

References (108)

1. D D'amours S Desnoyers I D'silva GG Poirier 1999 Poly (ADP-ribosyl)ation reactions in the regulation of nuclear functions J Biochem 342 249 268
2. RA Parise M Shawaqfeh MJ Egorin JH Beumer 2008 Liquid chromatography-mass spactometric assay for quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly (ADP-ribose) polymerase J Chromatogr B Analyt Technol Biomed Life Sci 872 1-2 141 147 18692448
3. H Hochegger D Dejsuphong T Fukushima C Morrison, et al. 2006 Parp-1 protects homologous recombination from interferenve by Ku and Ligase IV in vertebrate cells EMBO J 25 1305 1314 16498404
4. L Virag C Szabo 2002 The therapeutic potential of poly (ADP-ribose) polymerase inhibitors Pharmacol Rev 54 375 429 12223530
5. RG Meyer ML Meyer-Ficca EL Jacobson MK Jacobson 2003 Human poly (ADP-ribose) glycohydrolase (PARG) gene and the common promoter sequence it shares with inner mitochondrial membrane translocase 23 (TIM23) Gene 314 181 190 14527731
6. DW Koh AM Lawler MF Poitras, et al. 2004 Failure to degrade poly (ADP-ribose) increased sensitivity to cytotoxicity and early embryonic lethality PNAS 101 51 17699 17704 15591342
7. U Cortes WM Tong DL Coyle, et al. 2004 Depletion of the 110-Kilodalton isoform of poly (ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice MCB 24 16 7163 7178 15282315
8. MF Poitras DW Koh SW Yu, et al. 2007 Spatial and functional relationship between poly (ADP-ribose) polymerase-1 and Poly (ADP-ribose) glycohydrolase in the brain Neuroscience 148 1 198 211 17640816
9. M Miwa Matsutani 2007 PolyADP-ribosylation and cancer Cancer Sci 98 10 1528 1535 17645773
10. C Blenn FR Althaus M Manlanga 2006 Poly (ADP-ribose) glycohydrolase silencing protects against H2O2-induced cell death J Biochem 396 419 429
11. K Ratnam JA Low 2007 Current development of clinical poly (ADP-ribose) inhibitor in oncology Clin Cancer Res 13 5 1383 1388 17332279
12. P Decker EA Miranda G De Murcia S Muller 1999 An improved nonisotopic test to screen a large series of new inhibitor molecules of poly (ADP-ribose) polymerase activity for therapeutic applications Clin Cancer Res 5 1169 1172 10353753
13. S Cuzzocrea RD Paola E Mazzon, et al. 2005 PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion FASEB J 19 558 566 15791006
14. R Plummer C Jones M Middleton, et al. 2008 Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced Solid Tumors Clin Cancer Res 14 23 7917 7923 19047122
15. MT Valenzuela R Guerrerro MI Nunez, et al. 2002 PARP-1 modifies the effectiveness of P53 mediated DNA damage response Oncogene 21 7 1108 1116 11850828
16. SL Oei M Ziegler 2000 ATP for the DNA ligation step in base excision repair is generated from poly (ADP-ribose) J Biol Chem 275 23234 23239 10930429
17. N McCabe NC Turner CJ Lord, et al. 2006 Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition Cancer Res 66 16 8109 8115 16912188
18. Y Eguchi S Shimizu Y Tsujimoto 1997 Intracellular ATP levels determine cell death fate by apoptosis or necrosis Cancer Res 57 1835 1840 9157970 (Pubitemid 27209706)
19. SR Kumari H Mendoza-Alvarez R Alvarez-Gonzalez 1998 Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53by exogenous PARP and noncovalent binding of p53 to the Mr 85,000 proteolytic fragment1. Cancer Res 58 5075 5078 9823314
20. EB Affar M Germain E Winstall, et al. 2001 Caspase-3-mediated processing of poly (ADP-ribose) glycohydrolase during apoptosis JBC 276 4 2935 2942
21. DW Koh TM Dawson VL Dawson 2005 Mediation of cell death by Poly (ADP-ribose)-1 Pharmacol Res 52 1 5 14 15911329
22. Bhaskara, et al (2009) Differrential PARP cleavage: an indication for existence of multiple forms of cell death in human gilomas. Neurology India 57(3)
23. Q Hung YT Wu HL Tan CN Ong HM Shen 2009 A novel function of PARP-1 in modulation of autophagy and necrosis under oxidative stress Cell Death Diff 16 264 277
24. Y Lee E Shacter 1999 Oxidative stress inhibits apoptosis in human lymphoma cells J Bio Chem 274 19792 19798
25. JA Walisser RC Thies 1999 Poly (ADP-ribose) polymerase inhibition in oxidant stressed endothelial cells prevents oncosis and permits caspase activation and apoptosis Exp Cell Res 251 12 401 413 10471325
26. MT Mathews BC Berk 2008 PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2 Arterioscler Thromb Vasc Biol 28 711 717 18239155
27. K Kovacs A Toth P Deres, et al. 2006 Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion Biochem Pharmacol 71 4 441 452 16337154
28. +, as a PARP inhibitor and by partial restoration of mitochondrial function Pharmacology 69 3 150 157 14512702
29. DM Filipovic X Meng WB Reeves 1999 Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells Am J Physiol Renal Physiol 277 428 436
30. JP Roesner DA Vagts T Iber, et al. 2006 Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats Intensive Care Med 32 10 1649 1657 16927075
31. Oku H, Goto W, Tsujimoto M et al (2003) Effects of Poly(ADP-ribose) polymerase (PARP) Inhibitor on NMDA-induced retinal injury. Invest Ophthalmol Vis Sci 44: E-Abstract 27
32. + depletion in type I diabetes Nat Med 5 269 270 10086377
33. HC Ha SH Snyder 1999 Poly (ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion PNAS 96 13978 13982 10570184
34. S Hanai M Kanai S Ohashi, et al. 2004 Loss of poly (ADP-ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster PNAS 101 1 82 86 14676324
35. C Keil T Gröbe SL Oei 2006 MNNG-induced cell death is controlled by interactions between PARP-1, Poly (ADP-ribose) glycohydrolase, and XRCC1 J Biochem 281 34394 34405
36. J Ménissier-de Murcia M Mark O Wendling A Wynshaw-Boris G de Murcia 2001 Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development MCB 21 5 1828 1832
37. YG Yang U Cortes S Patnaik M Jasin Z Wang 2004 Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks Oncogene 23 3872 3882 15021907 [abstract]
38. T Nozaki M Masutani M Watanabe, et al. 1999 Syncytiotrophoblastic giant cells in Teratocarcinoma like tumors derived from Parp-disrupted mouse embryonic stem cells PNAS 96 23 13345 13350 10557323
39. A Saxena R Saffery LH Wong, et al. 2002 Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly (ADP-ribose) polymerase-1 protein and are poly (ADP-ribosyl) ated J Biol Chem 277 26921 26926 12011073
40. M Bhatia JB Kirkland KA Meckling-Gill 1996 Overexpression of poly (ADP-ribose) polymerase promotes cell cycle arrest and inhibits neutrophilic differentiation of NB4 acute promyelocytic leukemia cells Cell Growth Differ 7 1 91 100 8788037
41. M Bhatia JB Kirkland KA Meckling-Gill 1995 Modulation of poly (ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells J Biochem 308 131 137
42. K Harnacke M Kruhoffer TF Orntoft R Hass 2005 Down-modulation of poly(ADP-ribose) polymerase-1 (PARP-1) in human TUR leukemia cells restores transcriptional responsiveness for differentiation and cell cycle arrest Eur J Cell Biol 84 11 885 896 16323285 [abstract]
43. M Masutani T Nozaki M Watanabe, et al. 2001 Involvement of poly(ADP-ribose) polymerase in trophoblastic cell differentiation during tumorigenesis Mutant Res 477 111 117
44. M Shiokawa M Masutani H Fujihara, et al. 2005 Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors Jpn J Clin Oncol 35 2 97 102 15709096
45. MB Sevigny JM Silva WC Lan CC Alano RA Swanson 2003 Expression and activity of poly(ADP-ribose) glycohydrolase in cultured astrocytes, neurons, and C6 glioma cells Mol Brain Res 117 2 213 220 14559156 [abstract]
46. W Kraus J Lis 2003 PARP goes transcription Cell 113 6 677 683 12809599
47. R Pavri B Lewis TK Kim, et al. 2005 PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator Moll Cell 18 1 83 96 [abstract]
48. M Idogawa T Yamada K Honda, et al. 2005 Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex Gastroenterology 128 7 1919 1936 15940627 [abstract]
49. VA Soldatenkov A Albor BKR Patel, et al. 1999 Regulation of the human poly(ADP-ribose) polymerase promoter by ETS transcription factor Oncogene 18 27 3954 3962 10435618
50. H Ogino T Nozaki A Gunji, et al. 2007 Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells BMC Genomics 8 227 10.1186/1471-2164-8-227 (Pubitemid 47342544)
51. A Aldinussi G Gerlini S Fossati, et al. 2007 A key role for poly (ADP-ribose)-1 during human dendritic cell maturation J Immuno 179 305 312
52. K Zaniolo S Desnoyers S Leclerc S Guérin 2007 Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1 BMC Genomics 8 96 10.1186/1471-2199-8-96
53. WM Tong MP Hande PM Lansdorp ZQ Wang 2001 DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression Mol Cell Biol 21 12 4046 4054 11359911
54. CG Eberhart 2003 Medulloblastoma in mice lacking p53 and PARP Am J Pathol 162 1 7 10 12507884
55. SL Oei J Griesenbeck M Schweiger M Ziegler 1998 Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribosyl)ation of transcription factors JBC 273 31644 31647 (Pubitemid 29177091)
56. PO Hassa C Buerki C Lombardi R Imhof MO Hottiger 2003 Transcriptional coactivation of nuclear factor Kappa B-dependent gene expression by p300 is regulated by poly (ADP)-ribose polymerase-1 JBC 278 46 45145 45153
57. J Nie S Sakamoto D Song Z Qu K Ota T Taniguchi 1998 Interaction of Oct-1 and automodification domain of poly (ADP-ribose) synthetase FEBS Lett 424 1-2 27 32 9537509
58. TN Dear T Hainzl M Follo 1997 Identification of interaction partners for the basic-helix-loop-helix protein E47 Oncogene 14 891 898 9050988
59. AJ Butler CP Ordhal 1999 Poly (ADP-Ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription Mol Cell Boil 19 1 296 306
60. T Taniguchi M Agemori I Kameshita M Nishikimi Y Shizuta 1982 Participation of poly(ADP-ribosyl)ation in the depression of RNA synthesis caused by treatment of mouse lymphoma cells with methylnitrosourea J BC 257 4027 4030
61. T Shimokawa M Masutani S Nagasawa, et al. 1999 Isolation and cloning of rat poly (ADP-ribose) glycohydrolase: presence of a potential nuclear export signal conserved in mammalian orthologs J. Biochem 126 748 755 10502684
62. K Erdelyi A Kiss E Bankondi, et al. 2005 Gallotannin inhibits the expression of chemokines and inflammatory cytokines in A549 cells Mol Pharmacol 68 895 904 15976037
63. KM Frizzell MJ Gamble JG Berrocal 2009 Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells J Biol Chem 284 49 33926 33938 19812418 [abstract]
64. ZQ Wang L Stingl C Morrison, et al. 1997 PARP is important for genomic stability but dispensable in? Apoptosis Genes Dev 11 2347 2358 9308963
65. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 15 18 12516034
66. L Tentori PM Lacal A Muzi, et al. 2007 Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis Eur J Cancer 43 14 2124 2133 17714938
67. A Pyriochou G Olah EA Deitch C Szabo A Papapetropoulos 2008 Inhibition of angiogenesis by the poly (ADP-ribose) polymerase inhibitor PJ-34 IJMM 22 113 118
68. M Rajesh P Mukhopadhyay S Bátkai, et al. 2006 Pharmacological inhibition of poly (ADP-ribose) polymerase inhibits angiogenesis BBRC 350 2 352 357 17007818
69. M Rajesh P Mukhopadhyay G Godlewski 2006 Poly (ADP-ribose) polymerase inhibition decreases angiogenesis BBRC 350 4 1056 1062 17046715
70. NA Berger JW Adams GW Sikorski, et al. 1978 Synthesis of DNA and poly (Adenosine Diphosphate Ribose) in normal and chronic lymphocytic leukemia lymphocytes J Clin Inves 62 111 118
71. K Wielckens M Garbrecht M Kittler H Hilz 1980 ADP-ribosylation of nuclear proteins in normal lymphocytes and in low- grade malignant non-Hodgkin lymphoma cells Eur J Biochem 104 279 287 6245868
72. K Hirai K Ueda O Hayaishi 1983 Abberation of poly (adenosine diphosphate ribose) in human colon adenomatous polyps and cancers Cancer Res 43 3441 3446 6406058
73. M Fukushima OK Kuzuya K Ikai 1981 Poly (ADP-ribose) synthesis in human cervical cancer cell diagnostic cytological usefulness Cancer Lett 14 227 236 6277470
74. M Shiobara M Miyazaki H Ito, et al. 2001 Enhanced polyadenosine diphosphate ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma J Gastroenterol Hepatol 16 338 344 11339428
75. L Lin J Li YL Wang, et al. 2009 Relationship of PARG with colorectal carcinoma PARP, VEGF and b-FGF in colorectal carcinoma Chin J Cancer Res 21 2 135 141
76. Leal AP et al (2009) PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med (in press). Doi:10.1016
77. CJ Lord S McDonald S Swift, et al. 2008 A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity DNA Repair (Amst) 7 2010 2019
78. NC Turner CJ Lord E Iorns, et al. 2008 A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor EMBO J 27 9 1368 1377 18388863
79. A Ashworth 2008 A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 22 3785 3790 18591545
80. HE Bryant N Schultz HD Thomas, et al. 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 15829966 [abstract]
81. N Turner A Tutt A Ashworth 2005 Targeting the DNA repair defect of BRCA tumours Curr Opin Pharmacol 5 4 388 393 15955736
82. JA De Soto X Wang Y Tominaga, et al. 2006 The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors Int J Biol Sci 2 4 179 185 16810332
83. JA De Soto CX Deng 2006 PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int J Med Sci 3 4 117 123 16906222
84. NJ Curtin 2005 PARP inhibitors for cancer therapy Expert Rev Mol Med 7 4 1 20 15836799 [abstract]
85. X Liu Y Shi R Guan, et al. 2008 Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single stranded DNA damages to double-stranded DNA breaks Mol Cancer Res 6 10 1621 1629 18922977
86. S Suesse CJ Scholz A Buerkle LW Iler 2004 Poly (ADP-ribose) polymerase (PARP-1) and P53 independently function in regulating double strand break repair in primate cells Nucleic Acids Res 32 2669 2680
87. MR Purnell WJD Whish 1980 Novel inhibitors of poly (ADP-ribose) synthetase J Biochem 185 775 777
88. M Banasik H Komura M Shimoyama K Ueda 1992 Specific inhibitors of poly (ADP-ribose) synthetase and mono(ADP-ribosyl) transferase J Biol Chem 267 1569 1575 1530940
89. T Genovese R Di Paola P Catalano, et al. 2004 Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice Crit Care Med 32 6 1365 1374 15187521
90. Masutani M, Shimokawa T, Igarashi M et al (2002)Inhibition of poly(ADP-ribose) glycohydrolase activity by cyclic peptide antibiotics containing piperazic acid residues. Proceedings of the Japanese academy; Ser B, physical and biological sciences 78(1):15-17
91. L Formentini P Arapistas M Pitelli, et al. 2008 Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduced PARP-1 dependent cell death BJP 155 1235 1249
92. X Yang ME Lippman 1999 BRCA1 and BRCA2 in breast cancer Breast Cancer Res Treat 54 1 1 10 10369075
93. JA De Soto X Wang Y Tominaga, et al. 2006 The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors Int J Biol Sci 2 4 179 185 16810332
94. JA Munozo-Gamez D Martin-Olivia R Aguilar-Quesada 2005 PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis Biochem J 386 119 125
95. S Rottenberg JE Jaspers A Kersbergen, et al. 2008 High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs PNAS 105 44 17079 17084 18971340
96. Gopall R, Hong C & Yi S (2009) Gefitinib as monotherapy in the first-line setting in non-small cell lung Cancer. http://www.ispub.com/journal/ the-internet-journal-of-pulmonary-medicine/volume-11-number-2-5/article/ gefitinib-as-monotherapy-in-the-first-line-setting-in-non-small-cell-lung- cancer.html
97. JM Albert C Cao KW Kim, et al. 2007 Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models Clin Cancer Res 13 10 3033 3042 17505006
98. RJ Kinders M Hollingshead S Khin, et al. 2008 Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts Clin Cancer Res 14 21 6877 6885 18980982
99. CK Donawho Y Luo TD Penning, et al. 2007 ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 9 2728 2737 17473206
100. CR Calabrese MA Batey HD Thomas 2003 Identification of potent nontoxic poly (ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies Clin Cancer Res 9 2711 2718 12855651
101. LX Hao YL Wang L Cai LI YY 2007 Inhibitory effect of 5- Aminoisoquinolinone on Parp activity in colon carcinoma cell line HT-29 Chin J Cancer 26 6 566 571
102. M Li MD Threadgill YL Wang L Cai X Lin 2009 A poly (ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells Pathobiology 76 108 116 19468250
103. L Tentori I Portarena M Barbarino, et al. 2003 Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor Mol Pharmacol 63 192 202 12488552
104. L Tentori C Leonetti M Scarsella, et al. 2003 Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma Clin Cancer Res 9 5370 5379 14614022
105. L Tentori C Leonetti M Scarsella, et al. 2005 Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide Eur J Cancer 41 18 2948 2957 16288862
106. FA Dungey KW Caldecott AJ Chalmers 2009 Enhanced radiosensitisation of human glioma cells by combining inhibition of PARP with inhibition of Hsp90 Mol Cancer Ther 8 8 2243 2254 19671736
107. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 19553641
108. LT Gien HJ Mackay 2010 The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer J Oncol 10.1155/2010/151750 20049345